[en] The TORCH study (Towards a Revolution in COPD Health) was a double-blind, randomised, placebo-controlled clinical trial, investigating the combination of salmeterol/fluticasone propionate for 3 years in COPD. The primary end point was on all-cause mortality. Secondary end points included COPD exacerbation rate, lung function and health status. More than 6000 patients were randomised. In this article, we briefly report the most significant results of the study. The efficacy on mortality (reduction of the risk of death of 17.5%) was near the predetermined level of statistical significance (p = 0.052); the combination had a significant effect on the three pillars of COPD management, that is: improvement of quality of life and respiratory function, and reduction of the rate of exacerbations. In addition to being effective, the combination salmeterol/fluticasone (50/500 microg 2x/day) is well tolerated in COPD and had a favourable benefit/risk ratio.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Corhay, Jean-Louis ; Centre Hospitalier Universitaire de Liège - CHU > Pneumologie-Allergologie
Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie
Language :
French
Title :
L'etude clinique du mois. L'etude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la sante des patients souffrant de BPCO
Alternative titles :
[en] Clinical Study of the Month: The Torch Study (Towards a Revolution in Copd Health)
Publication date :
April 2007
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Lopez AD, Shibuya K, Rao C, et al. - Chronic obstructive pulmonary disease : current burden and future projections - Supplementary material. Eur Respir J. 2006, 27, 397-412.
Murray CJ, Lopez AD. - Alternative projections of mortality and disability by cause 1990-2020 : Global Burden of Disease Study. Lancet. 1997, 349, 1498-1504.
Corhay JL, Nguyen D, Louis R. - Les exacerbations dans la BPCO : un fardeau à réduire. Rev Med Liège. 2006, 61, 691-696.
Anthonisen NR, Skeans MA, Wise RA, et al. - The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005, 142, 233-239.
Nocturnal Oxygen Therapy Trial Group. - Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease : a clinical trial. Ann Intern Med, 1980, 93, 391-398
Medical Research Council Working Party. - Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet, 1981, 1, 681-686.
Fishman, A, Martinez F, Naunheim K, et al. - A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med, 2003, 348, 2059-2073.
Sin DD, Wu L, Anderson JA, Athonisen NR, et al. - Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax, 2005, 60, 992-997.
Soriano JB, Vestbo J, Pride NB, et al. - Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J, 2002, 20, 819-825.
Mapel DW, Hurley JS, Roblin D, et al. - Survival of COPD patients using inhaled corticosteroids and long-acting beta-agonists. Respir Med, 2006, 100, 595-609.
The TORCH Study Group. - The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J, 2004, 24, 206-210.
Calverley PMA, Anderson JA, Celli B, et al, for the TORCH investigators. - Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 2007, 356, 775-789.
Burge PS, Calverley PMA, Jones PW, et al. - Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease : the ISOLDE trial. BMJ, 2000, 320, 1297-1303.
Mahler DA, Wire P, Horstman D, et al. - Effectiveness of fluticasone propionate and salmeterol combination delivered via the discus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2002, 166, 1084-1091.
Calverley P, Pauwels R, Vestbo J, et al. - Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, 2003, 361, 449-456.
Szafranski W, Cukier A, Ramirez A, et al. - Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J, 2003, 21, 74-81.
Pauwels RA, Buist AS, Calverley PMA, et al. - Global strategy for the diagnosis, management, and prevention of chronic obstructive disease : NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop report. Am J Respir Crit Care Med, 2001, 163, 1256-1276 (updated 2003; available at www.goldcopd.com. Accessed December 19, 2003).
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.